National Asset Management Inc. Purchases 28,283 Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS)

National Asset Management Inc. lifted its stake in shares of Vivos Therapeutics, Inc. (NASDAQ:VVOSGet Rating) by 55.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 79,270 shares of the company’s stock after purchasing an additional 28,283 shares during the quarter. National Asset Management Inc. owned 0.34% of Vivos Therapeutics worth $179,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of VVOS. Boston Partners acquired a new stake in Vivos Therapeutics during the 3rd quarter worth approximately $188,000. Russell Investments Group Ltd. bought a new stake in Vivos Therapeutics during the 3rd quarter valued at $188,000. Avalon Investment & Advisory increased its stake in Vivos Therapeutics by 73.6% during the 3rd quarter. Avalon Investment & Advisory now owns 329,322 shares of the company’s stock valued at $1,330,000 after purchasing an additional 139,583 shares in the last quarter. BlackRock Inc. increased its stake in Vivos Therapeutics by 255.8% during the 3rd quarter. BlackRock Inc. now owns 48,905 shares of the company’s stock valued at $198,000 after purchasing an additional 35,158 shares in the last quarter. Finally, Blueshift Asset Management LLC bought a new stake in Vivos Therapeutics during the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 11.32% of the company’s stock.

Shares of Vivos Therapeutics stock opened at $1.96 on Monday. Vivos Therapeutics, Inc. has a 12-month low of $1.63 and a 12-month high of $10.86. The company has a market cap of $45.10 million, a price-to-earnings ratio of -2.00 and a beta of -0.45. The company’s 50-day moving average price is $2.71 and its 200-day moving average price is $2.92.

Separately, Zacks Investment Research downgraded shares of Vivos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday.

Vivos Therapeutics Profile (Get Rating)

Vivos Therapeutics, Inc, a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA.

See Also

Institutional Ownership by Quarter for Vivos Therapeutics (NASDAQ:VVOS)

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.